Boston Scientific（BSX）株式概要
ボストン・サイエンティフィック・コーポレーションは、世界中の様々なインターベンショナル医療分野で使用される医療機器の開発、製造、販売を行っている。 詳細
BSX Community Fair Values
Create NarrativeSee what 183 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$98.9
FV
50.1% 割安 内在価値ディスカウント9.80%
Revenue growth p.a.
754
users have viewed this narrative1users have liked this narrative
1users have commented on this narrative
26users have followed this narrative
Boston Scientific Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$49.37 |
| 52週高値 | US$109.50 |
| 52週安値 | US$42.20 |
| ベータ | 0.57 |
| 1ヶ月の変化 | 14.31% |
| 3ヶ月変化 | -14.56% |
| 1年変化 | -53.07% |
| 3年間の変化 | -2.10% |
| 5年間の変化 | 10.55% |
| IPOからの変化 | 1,053.17% |
最新ニュース
ナラティブ更新 • Aug 11
BSX: Electrophysiology And Watchman Headwinds Will Pressure Future Returns
Analysts have cut their price targets on Boston Scientific in recent months, and the model fair value estimate has been reduced from $69.00 to $44.00 as expectations reset around slower revenue growth, slightly lower profit margins, a reduced future P/E, and updated guidance on key products like Watchman and electrophysiology. Analyst Commentary Recent Street research on Boston Scientific points to a clear reset in expectations.Seeking Alpha • Aug 11
Boston Scientific: The $5.4 Billion Quarter Tells Me The Sell-Off Is Overdone
Summary Boston Scientific has been heavily sold off, now trading at attractive valuations versus peers after multiple guidance cuts. Despite U.S. growth headwinds for WATCHMAN and electrophysiology, BSX delivered strong Q2 2026 results with 7.5% sales growth and 14.7% adjusted EPS growth. International markets are driving robust growth for BSX, with electrophysiology up 23.1% and WATCHMAN up 17.7% outside the U.S. Strong free cash flow ($1.29B Q2, $3.8B FY forecast) enables innovation, acquisitions, and potential share repurchases; I rate BSX a strong buy at current levels. Read the full article on Seeking Alpha分析記事 • Aug 07
Boston Scientific Corporation (NYSE:BSX) Just Reported, And Analysts Assigned A US$62.69 Price Target
Investors in Boston Scientific Corporation ( NYSE:BSX ) had a good week, as its shares rose 7.2% to close at US$49.30...Recent updates
ナラティブ更新 • Aug 11
BSX: Electrophysiology And Watchman Headwinds Will Pressure Future Returns
Analysts have cut their price targets on Boston Scientific in recent months, and the model fair value estimate has been reduced from $69.00 to $44.00 as expectations reset around slower revenue growth, slightly lower profit margins, a reduced future P/E, and updated guidance on key products like Watchman and electrophysiology. Analyst Commentary Recent Street research on Boston Scientific points to a clear reset in expectations.Seeking Alpha • Aug 11
Boston Scientific: The $5.4 Billion Quarter Tells Me The Sell-Off Is Overdone
Summary Boston Scientific has been heavily sold off, now trading at attractive valuations versus peers after multiple guidance cuts. Despite U.S. growth headwinds for WATCHMAN and electrophysiology, BSX delivered strong Q2 2026 results with 7.5% sales growth and 14.7% adjusted EPS growth. International markets are driving robust growth for BSX, with electrophysiology up 23.1% and WATCHMAN up 17.7% outside the U.S. Strong free cash flow ($1.29B Q2, $3.8B FY forecast) enables innovation, acquisitions, and potential share repurchases; I rate BSX a strong buy at current levels. Read the full article on Seeking Alpha分析記事 • Aug 07
Boston Scientific Corporation (NYSE:BSX) Just Reported, And Analysts Assigned A US$62.69 Price Target
Investors in Boston Scientific Corporation ( NYSE:BSX ) had a good week, as its shares rose 7.2% to close at US$49.30...
ナラティブ更新 • Jul 28
BSX: Long-Term Pipeline And Buybacks Will Counter Watchman Uncertainty
Boston Scientific's updated analyst price target of $72.25, compared with the prior $75.00 fair value estimate, reflects a broad wave of Street target cuts as analysts factor in softer Watchman and electrophysiology expectations, while still pointing to intact fundamentals and underappreciated growth areas. Analyst Commentary Recent Street research on Boston Scientific points to a reset in expectations around Watchman and electrophysiology, while still highlighting core strengths in the broader portfolio.
ナラティブ更新 • Jul 14
BSX: Reset Growth Expectations Will Set Stage For Future Recovery Potential
Analyst price targets for Boston Scientific have been revised downward by roughly $25 to $30 as analysts factor in softer Watchman growth, ongoing electrophysiology headwinds, and slightly more conservative assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent research on Boston Scientific points to a mixed but still constructive backdrop, with many firms trimming price targets while maintaining positive ratings.ナラティブ更新 • Jun 30
BSX: Clinical Pipeline Strength Will Offset Watchman Reset And Sector Headwinds
The analyst price target for Boston Scientific has been reduced by $2.10, from $77.10 to $75.00, as analysts factor in slower Watchman growth, lower utilization trends, and more conservative long term revenue and margin assumptions across the medtech sector. Analyst Commentary Recent research on Boston Scientific points to a clear split between optimism on the broader business and caution around Watchman and utilization trends.分析記事 • Jun 19
Boston Scientific (BSX) Stock Could Be 54.2% Undervalued After Soft 2026 Guidance
Boston Scientific (BSX) shares have come under pressure after the company issued 2026 guidance that fell short of market expectations, with investors focusing on slowing revenue growth in its electrophysiology segment. See our latest analysis for Boston Scientific. At a share price of $45.29, Boston Scientific has seen pressure build, with the 30 day share price return down 20.28% and the year to date share price return down 52.18%. The 1 year total shareholder return is down 55.32%, pointing...ナラティブ更新 • Jun 16
BSX: Clinical Pipeline And Share Repurchases Will Support Rebased Expectations
Boston Scientific's fair value estimate has been trimmed from $79.40 to $77.10, as analysts lower price targets across the sector and factor in slower Watchman growth, a more cautious utilization backdrop, and slightly reduced long term revenue and margin assumptions. Analyst Commentary Recent Street research on Boston Scientific clusters around a similar theme, with most firms trimming price targets and revisiting assumptions on growth, margins, and valuation after the latest Watchman commentary and a softer utilization backdrop.ナラティブ更新 • Jun 01
BSX: Clinical Pipeline And Capital Deployment Will Support Rebased Expectations
Boston Scientific's updated analyst price target has shifted lower by about $5.80 to $79.40, as analysts factor in slower growth expectations for the Watchman franchise and slightly softer forecasts for revenue growth, profit margins, and future P/E. Analyst Commentary Recent Street research around Boston Scientific reflects a mix of optimism and caution, with most firms trimming price targets to align with updated expectations for the Watchman franchise, organic sales growth, and sector-wide medtech valuations.ナラティブ更新 • May 08
BSX: Clinical Wins And Pipeline Strength Will Support Rebased Expectations
Analysts have trimmed the Boston Scientific fair value estimate from $95.75 to $85.19 after a series of price target cuts across the Street. The change reflects updated assumptions for slower revenue growth, slightly higher profit margins, and a lower forward P/E multiple.新しいナラティブ • Apr 24
Minimally Invasive Therapies And Atrial Fibrillation Treatments Will Support Steady Prospects Ahead
Catalysts About Boston Scientific Boston Scientific is a global medical technology company that develops and sells devices used in cardiology, electrophysiology, urology, endoscopy, neuromodulation and other interventional procedures. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Apr 22
BSX: Clinical Trial Wins Will Offset Reset Expectations And Battery Concerns
Analysts have trimmed the fair value estimate for Boston Scientific to $95.75 from $100.31, reflecting a series of lower Street price targets and slightly more conservative assumptions on growth, profitability, and future P/E multiples. Analyst Commentary Recent research coverage on Boston Scientific has centered on a broad reset of expectations, with many firms revising price targets and, in some cases, ratings.新しいナラティブ • Apr 08
Pulsed Field Ablation And Minimally Invasive Therapies Will Reshape Long Term Procedure Volumes
Catalysts About Boston Scientific Boston Scientific develops and sells medical devices across cardiovascular, electrophysiology, neuromodulation, endoscopy, urology and related therapeutic areas worldwide. What are the underlying business or industry changes driving this perspective?ナラティブ更新 • Apr 07
BSX: Clinical Wins And 2026 Outlook Will Outweigh Pacemaker Battery Concerns
Boston Scientific's analyst fair value estimate shifts modestly lower from $102.00 to about $100.31, as analysts recalibrate price targets across the group following recent clinical data, rating changes, and updated sector models. Analyst Commentary Recent Street research around Boston Scientific clusters around a common theme, with many firms trimming price targets and a smaller group highlighting potential upside tied to execution and clinical progress.ナラティブ更新 • Mar 24
BSX: Reorganized Segments And 2026 Outlook Should Offset Recent Pacemaker Headlines
Analysts have trimmed the Boston Scientific fair value estimate by about $2 to $102, reflecting a series of reduced Street price targets that incorporate slightly lower revenue growth assumptions, a marginally higher discount rate, and modest tweaks to long term margin and future P/E expectations. Analyst Commentary Street research on Boston Scientific has been active, with most recent moves clustered around price target resets and list changes.ナラティブ更新 • Mar 08
BSX: Reorganized Segments And 2026 Outlook Should Support Sentiment Rebound
Analysts have trimmed their blended price target on Boston Scientific by about $0.50 to roughly $104.25. This reflects updated models following the company reorganization and recent management commentary.ナラティブ更新 • Feb 22
BSX: Organizational Changes Should Support Rebound As 2026 Patterns Normalize
Analysts have trimmed their average price target on Boston Scientific to $104.75 from $108.66, citing updated models that factor in recent organizational changes and management commentary following the latest earnings call. Analyst Commentary Across Wall Street, most research updates on Boston Scientific center on revised models and valuation resets rather than outright changes in long term views.ナラティブ更新 • Feb 06
BSX: Execution Outperformance Should Drive Rebound As 2026 Patterns Normalize
The analyst price target for Boston Scientific has been reduced by about $17 to align with updated Street research. This reflects slightly lower revenue growth assumptions, a modestly higher discount rate, and a lower future P/E multiple, while profit margin expectations remain steady.
新しいナラティブ • Jan 25
BSX after Penumbra ?
The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: * Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.ナラティブ更新 • Jan 10
BSX: Shares Should Rise On Execution Outperformance And 2026 Normalization Potential
Analysts have trimmed their Boston Scientific fair value estimate slightly to about $125.45 from $125.86, reflecting fine tuning of discount rate, revenue growth, profit margin and future P/E assumptions in light of recent price target resets and largely supportive research commentary across the MedTech sector. Analyst Commentary Recent Street research on Boston Scientific reflects generally constructive views on execution and growth, with some recalibration of targets as models are updated after quarterly results and sector wide resets.ナラティブ更新 • Dec 25
BSX: Shares Will Rise On Execution Outperformance And Three Year Growth Plan
Analysts have nudged their fair value estimate for Boston Scientific slightly lower to approximately $126 per share, even as multiple firms have lifted price targets into the $124 to $136 range, citing sustained double digit revenue growth, a robust pipeline, and potential upside from recent acquisitions and Q3 outperformance. Analyst Commentary Bullish analysts largely frame Boston Scientific as a durable double digit grower with room for further multiple expansion, pointing to recent Q3 upside, raised long term targets, and a steady cadence of accretive deals as support for valuations near or above current levels.ナラティブ更新 • Dec 11
BSX: Shares Will Rise On Earnings Strength And Multi Year Execution Momentum
Analysts nudged their average price target for Boston Scientific modestly higher, toward the low to mid $130 range, citing the company’s Q3 beat, accelerating Watchman adoption, confidence in multi year guidance, and a robust growth pipeline supported by strategic acquisitions like Nalu, despite some cautions on valuation and longer term growth moderation. Analyst Commentary Analyst reaction to Boston Scientific's latest results and strategic updates has been predominantly positive, with several firms raising price targets and reiterating favorable ratings, while a minority voice has started to flag valuation and medium term growth risks.ナラティブ更新 • Nov 27
BSX: Shares Will Advance On Earnings Strength And Merger Execution Momentum
Boston Scientific's analyst price targets have been raised by several dollars, with most now clustered around $130 per share. Analysts highlight robust quarterly results, accelerating growth segments, and confidence in the company’s long-range outlook.ナラティブ更新 • Nov 07
BSX: Shares Will See Momentum From Recent Acquisition And Execution Confidence
Boston Scientific's analyst price target has been increased modestly, with the consensus now reflecting a higher fair value in addition to ongoing confidence in robust growth prospects and recent business performance, as analysts cite solid quarterly results, improving guidance, and successful strategic acquisitions. Analyst Commentary Recent analyst research on Boston Scientific highlights both optimistic and cautious perspectives regarding the company's valuation, strategic moves, and long-term growth outlook.ナラティブ更新 • Oct 24
Future Growth Plans And Acquisitions Will Drive Broader Market Expansion
Analysts have raised their price target for Boston Scientific to approximately $126, up from $124.53. They cite renewed confidence in the company’s earnings outlook, along with improvements in profit margin and future growth expectations, following strong quarterly performance.株主還元
| BSX | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | -4.5% | -1.2% | -2.1% |
| 1Y | -53.1% | -12.8% | 18.8% |
業界別リターン: BSX過去 1 年間で-12.8 % の収益を上げたUS Medical Equipment業界を下回りました。
リターン対市場: BSXは、過去 1 年間で18.8 % のリターンを上げたUS市場を下回りました。
価格変動
| BSX volatility | |
|---|---|
| BSX Average Weekly Movement | 5.6% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: BSX 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: BSXの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1979 | 59,000 | Mike Mahoney | www.bostonscientific.com |
ボストン・サイエンティフィック・コーポレーションは、様々なインターベンショナル医療分野で使用される医療機器の開発、製造、販売を世界中で行っている。同社はMedSurgとCardiovascularの2つのセグメントで事業を展開している。膵胆道系の診断・治療や内視鏡的逆行性胆管膵管造影に使用する単回使用スコープSpyGlass、単回使用十二指腸内視鏡など、さまざまな消化器疾患の診断・治療用機器や、内視鏡手術・感染予防製品を提供している；尿管ステント、カテーテル、バスケット、ガイドワイヤー、排尿・腸機能障害、シース、バルーン、単回使用デジタル式軟性尿管鏡、ホルミウムレーザーシステム、陰茎インプラント、人工尿道括約筋、レーザーシステム、ハイドロゲルシステムなどの泌尿器科疾患治療用機器、脊髄刺激システム、高周波焼灼術、骨内神経焼灼術、脳深部刺激システムなどの神経運動障害治療および慢性疼痛管理用機器。また、心臓のさまざまな疾患や異常を診断・治療する技術、左心房付属器閉鎖（LAAC）装置であるWATCHMAN FLX、心臓をモニターし、心臓の異常を治療するために電気を供給する植込み型装置（除細動器、心臓再同期療法除細動器、MRI S-ICDシステム、心臓再同期療法ペースメーカー、遠隔患者管理システム、挿入型心臓モニターシステム、遠隔心臓モニターシステムなど）も提供している。さらに、心臓の速度およびリズム障害、末梢動脈および静脈疾患の診断および治療、がんの診断および治療用の製品も提供している。同社は1979年に設立され、マサチューセッツ州マールボロに本社を置いている。
Boston Scientific Corporation 基礎のまとめ
| BSX 基礎統計学 | |
|---|---|
| 時価総額 | US$75.37b |
| 収益（TTM） | US$3.67b |
| 売上高(TTM) | US$21.00b |
19.5x
PER（株価収益率3.4x
P/SレシオBSX は割高か？
公正価値と評価分析を参照収益と収入
| BSX 損益計算書（TTM） | |
|---|---|
| 収益 | US$21.00b |
| 売上原価 | US$6.47b |
| 売上総利益 | US$14.53b |
| その他の費用 | US$10.85b |
| 収益 | US$3.67b |
直近の収益報告
Jun 30, 2026
次回決算日
Oct 28, 2026
| 一株当たり利益（EPS） | 2.54 |
| グロス・マージン | 69.19% |
| 純利益率 | 17.50% |
| 有利子負債／自己資本比率 | 49.7% |
BSX の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/20 09:33 |
| 終値 | 2026/08/20 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Boston Scientific Corporation 29 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。58
| アナリスト | 機関 |
|---|---|
| Jasper Hellweg | Argus Research Company |
| David Rescott | Baird |
| null null | Baird |